BD buys flow cytometry technology firm Cytognos

By Erik L. Ridley, contributing writer

February 1, 2022 -- Becton Dickinson (BD) has acquired flow cytometry technology developer Cytognos from Spanish firm Vitro. Technology developed by Cytognos is used to diagnose blood cancer and detect minimal residual disease (MRD), according to the vendors.

In addition to use in MRD applications, the Cytognos technology can also be utilized in immune monitoring research for blood diseases. Terms of the deal were not disclosed.

For BD, the deal accelerates its strategy to support chronic disease management by expanding its portfolio of blood cancer diagnostics, immune assessment tests, and informatics, according to the firm. BD also gains exclusive access to advanced assays licensed by Cytognos from the EuroFlow Consortium; the firm already has existing license agreements with the EuroFlow Consortium for multiple other assays.

In addition, BD said that Cytognos' key products expand its portfolio of diagnostic and research technology for certain types of cancers that use flow cytometry, including lymphoma, leukemia, and multiple myeloma, according to the vendor. Its IVD products have the CE Mark but are not available for sale in the U.S.

Cytognos also provides several research assays for multiple myeloma MRD and immune monitoring. Cytognos CEO Fernando Martin de Lara will continue on with BD as business leader, and the company's approximately 80 employees will join BD.

An investor in Cytognos since 1996, Vitro acquired a majority stake in the company in 2018. Vitro said it divested Cytognos to focus on the launch of new IVD platforms in 2022.

Vitro is currently in the process of setting up independent units to manage its existing reagents, hardware, and software diagnostics teams; these units focus on molecular biology, anatomic pathology, and direct-to-consumer women's health services, according to the Seville, Spain-based company.

BD Cor system features MX instrument for infectious diseases
Becton Dickinson (BD) recently expanded its BD Cor system to include a new MX instrument for molecular testing of infectious diseases.
The next phase of diagnostic testing is here and ready to scale
The new COVID-19 landscape combined with the arduous shifts in healthcare staffing further supports the integration of automation in diagnostics. While...
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
BD secures BARDA funds for development of COVID-19 test
Becton Dickinson (BD) has secured $24.7 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop...
BD launches new BD Cor molecular diagnostics system
Becton Dickinson (BD) has launched a robotics-based, high-throughput molecular diagnostic system called BD Cor that will be available to labs in the U.S....

Copyright © 2022

Last Updated bc 2/3/2022 7:13:14 AM